GPT and fatty liver disease: A minority (7.9%) of participants experienced ≥1 hepatic adverse events, the most common being gamma-glutamyl transferase increased (2.5%), alanine aminotransferase increased (1.9%), hepatic enzyme increased (1.6%), hepatic steatosis (1.5%), cholelithiasis (1.4%), and aspartate aminotransferase increased (1.3%).